Literature DB >> 31243614

Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis.

Sonja Rothweiler1, Linda Feldbrügge1,2, Zhenghui Gordon Jiang1, Eva Csizmadia1, Maria Serena Longhi1, Kahini Vaid1, Keiichi Enjyoji1, Yury V Popov3, Simon C Robson4.   

Abstract

Purinergic signaling is important in the activation and differentiation of macrophages, which play divergent roles in the pathophysiology of liver fibrosis. The ectonucleotidase CD39 is known to modulate the immunoregulatory phenotype of macrophages, but whether this specifically impacts cholestatic liver injury is unknown. Here, we investigated the role of macrophage-expressed CD39 on the development of biliary injury and fibrosis in a mouse model of sclerosing cholangitis. Myeloid-specific CD39-deficient mice (LysMCreCd39fl/fl) were generated. Global CD39 null (Cd39-/-), wild-type (WT), LysMCreCd39fl/fl, and Cd39fl/fl control mice were exposed to 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) to induce biliary fibrosis. Hepatic hydroxyproline levels, liver histology, immunohistochemistry, mRNA expression levels, and serum biochemistry were then assessed. Following 3 weeks of DDC-feeding, Cd39-/- mice exhibited more severe fibrosis, when compared to WT mice as reflected by morphology and increased liver collagen content. Myeloid-specific CD39 deletion in LysMCreCd39fl/fl mice recapitulated the phenotype of global Cd39-/-, after exposure to DDC, and resulted in similar worsening of liver fibrosis when compared to Cd39fl/fl control animals. Further, DDC-treated LysMCreCd39fl/fl mice exhibited elevated serum levels of transaminases and total bilirubin, as well as increased hepatic expression of the profibrogenic genes Tgf-β1, Tnf-α, and α-Sma. However, no clear differences were observed in the expression of macrophage-elaborated specific cytokines between LysMCreCd39fl/fl and Cd39fl/fl animals subjected to biliary injury. Our results in the DDC-induced biliary type liver fibrosis model suggest that loss of CD39 expression on myeloid cells largely accounts for the exacerbated sclerosing cholangitis in global CD39 knockouts. These findings indicate that macrophage expressed CD39 protects from biliary liver injury and fibrosis and support a potential therapeutic target for human hepatobiliary diseases.

Entities:  

Keywords:  CD39; Kupffer cells; Liver fibrosis; Primary sclerosing cholangitis; Purinergic signaling

Year:  2019        PMID: 31243614      PMCID: PMC6737175          DOI: 10.1007/s11302-019-09664-3

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  41 in total

Review 1.  Macrophage activation and polarization.

Authors:  Fernando Oneissi Martinez; Antonio Sica; Alberto Mantovani; Massimo Locati
Journal:  Front Biosci       Date:  2008-01-01

Review 2.  Liver macrophages in tissue homeostasis and disease.

Authors:  Oliver Krenkel; Frank Tacke
Journal:  Nat Rev Immunol       Date:  2017-03-20       Impact factor: 53.106

Review 3.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

4.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.

Authors:  K Enjyoji; J Sévigny; Y Lin; P S Frenette; P D Christie; J S Esch; M Imai; J M Edelberg; H Rayburn; M Lech; D L Beeler; E Csizmadia; D D Wagner; S C Robson; R D Rosenberg
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

Review 5.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.

Authors:  Simon C Robson; Yan Wu; Xiaofeng Sun; Christoph Knosalla; Karen Dwyer; Keiichi Enjyoji
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

Review 6.  Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.

Authors:  Yury Popov; Detlef Schuppan
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

7.  Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice.

Authors:  Jean-Philippe Pradere; Johannes Kluwe; Samuele De Minicis; Jing-Jing Jiao; Geum-Youn Gwak; Dianne H Dapito; Myoung-Kuk Jang; Nina D Guenther; Ingmar Mederacke; Richard Friedman; Ana-Cristina Dragomir; Costica Aloman; Robert F Schwabe
Journal:  Hepatology       Date:  2013-08-09       Impact factor: 17.425

Review 8.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

9.  Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice.

Authors:  Yury Popov; Deanna Y Sverdlov; Anisha K Sharma; K Ramakrishnan Bhaskar; Shaoyong Li; Tobias L Freitag; James Lee; Walburga Dieterich; Gerry Melino; Detlef Schuppan
Journal:  Gastroenterology       Date:  2011-01-26       Impact factor: 22.682

Review 10.  Molecular mechanisms that influence the macrophage m1-m2 polarization balance.

Authors:  Nan Wang; Hongwei Liang; Ke Zen
Journal:  Front Immunol       Date:  2014-11-28       Impact factor: 7.561

View more
  10 in total

Review 1.  Hypoxia-inducible factors and innate immunity in liver cancer.

Authors:  Vincent Wai-Hin Yuen; Carmen Chak-Lui Wong
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

2.  Genome-Wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin.

Authors:  Pei-Suen Tsou; Pamela J Palisoc; Mustafa Ali; Dinesh Khanna; Amr H Sawalha
Journal:  Arthritis Rheumatol       Date:  2021-07-07       Impact factor: 15.483

3.  Toll-Like Receptor-Mediated Activation of CD39 Internalization in BMDCs Leads to Extracellular ATP Accumulation and Facilitates P2X7 Receptor Activation.

Authors:  Ronglan Zhao; Jinjuan Qiao; Xumei Zhang; Yansong Zhao; Xiangying Meng; Deming Sun; Xiaoxiang Peng
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

4.  Ecto-Nucleotide Triphosphate Diphosphohydrolase-2 (NTPDase2) Deletion Increases Acetaminophen-Induced Hepatotoxicity.

Authors:  Linda Feldbrügge; Katrin Splith; Ines Kämmerer; Sandra Richter; Anna Riddermann; Santiago Andres Ortiz Galindo; Felix Krenzien; Tobias Müller; Eva Csizmadia; Johann Pratschke; Simon C Robson; Moritz Schmelzle
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

5.  Phagocyte Chemoattraction Is Induced through the Mcp-1-Ccr2 Axis during Efferocytosis.

Authors:  Sang-Ah Lee; Deokhwan Kim; Chanhyuk Min; Byeongjin Moon; Juyeon Lee; Hyunji Moon; Susumin Yang; Chang Sup Lee; Gwangrog Lee; Daeho Park
Journal:  Cells       Date:  2021-11-10       Impact factor: 6.600

Review 6.  The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.

Authors:  Kevin De Muynck; Bart Vanderborght; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

Review 7.  Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases.

Authors:  Erika Y Faraoni; Cynthia Ju; Simon C Robson; Holger K Eltzschig; Jennifer M Bailey-Lundberg
Journal:  Front Physiol       Date:  2022-03-14       Impact factor: 4.755

8.  Negative feedback control of neuronal activity by microglia.

Authors:  Ana Badimon; Hayley J Strasburger; Pinar Ayata; Xinhong Chen; Aditya Nair; Ako Ikegami; Philip Hwang; Andrew T Chan; Steven M Graves; Joseph O Uweru; Carola Ledderose; Munir Gunes Kutlu; Michael A Wheeler; Anat Kahan; Masago Ishikawa; Ying-Chih Wang; Yong-Hwee E Loh; Jean X Jiang; D James Surmeier; Simon C Robson; Wolfgang G Junger; Robert Sebra; Erin S Calipari; Paul J Kenny; Ukpong B Eyo; Marco Colonna; Francisco J Quintana; Hiroaki Wake; Viviana Gradinaru; Anne Schaefer
Journal:  Nature       Date:  2020-09-30       Impact factor: 69.504

Review 9.  Contribution of Macrophage Efferocytosis to Liver Homeostasis and Disease.

Authors:  Andrea Kristina Horst; Gisa Tiegs; Linda Diehl
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

Review 10.  Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?

Authors:  Xin Huang; Yimin Khoong; Chengyao Han; Dai Su; Hao Ma; Shuchen Gu; Qingfeng Li; Tao Zan
Journal:  Front Physiol       Date:  2021-07-15       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.